The Lancet
Media & Internet · United Kingdom · 201-500 Employees
View Company Info for Free
Overview
Headquarters
125 London Wall, London, Greater London,...Phone Number
+44 2074244950Website
www.thelancet.comRevenue
$33.2 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About The Lancet
Founded in 1823, The Lancet is an independent, international weekly general medical journal that is committed to applying scientific knowledge to improve health and advance human progress. The company is headquartered in London, United Kingdom.Explore more
The Lancet Org Chart
MV
Administrativo
AM
Admin
LM
Phlebotomy Technician
SA
Chief Editor
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is The Lancet your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at The Lancet
Earning: See what the market has to say on The Lancet recently announced quarterly report
Website visits: Recent activity has been detected on your website
Click to see if The Lancet had a recent Job posting/layoffs
Product Launch: Get notified when The Lancet launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if The Lancet is spiking on competitors!
The Lancet, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once The Lancet has new funding data
Check if The Lancet has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Find VP level buyers at The Lancet
Find more new buyers
Compare Similar Companies to The Lancet
Compare insights from companies similar to The Lancet, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
The Lancet is experiencing very low activity levels compared to other companies in the Media & Internet sector.
What does this means?
The Lancet is drawing exceptional interest within the Media & Internet industry, suggesting notable developments or strong market momentum, learn more about The Lancet.
The Lancet Tech Stack
A closer look at the technologies used by The Lancet
See more technologies
Most Recent Scoops
Person-Based
Person-Based
Events
Person-Based
Lawsuits, Legal Affairs
Person-Based
Partnership, Medical Research
Person-Based
Medical Research
The Lancet News & Media
PeproMene Bio Announces Publication in The Lancet of Breakthrough Phase 1 Clinical Trial Results Demonstrating Deep and Durable Complete Responses in Relapsed/Refractory B-cell Lymphomas, including after prior CD19 CAR T-cell failure
IRVINE, Calif., Sept. 8, 2026 /PRNewswire/ -- PeproMene Bio, Inc. today announced the publication in The Lancet, one of the world's leading medical journals, of results from its Phase 1 clinical trial evaluating PMB-CT01, the company's first-in-class BAFF-R-targeted CAR T-cell therapy, in...PeproMene Bio Announces Publication in The Lancet of Breakthrough Phase 1 Clinical Trial Results Demonstrating Deep and Durable Complete Responses in Relapsed/Refractory B-cell Lymphomas, including after prior CD19 CAR T-cell failure
IRVINE, Calif., Sept. 8, 2026 /PRNewswire/ -- PeproMene Bio, Inc. today announced the publication in The Lancet, one of the world's leading medical journals, of results from its Phase 1 clinical trial evaluating PMB-CT01, the company's first-in-class BAFF-R-targeted CAR T-cell therapy, in...Nektar Announces Publication in The Lancet of Positive Phase 2b REZOLVE-AD 16-Week Induction Results of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis
REZOLVE-AD study met all primary and key secondary endpoints, including EASI-75, EASI-90, Itch NRS, vIGA-AD and BSA, on rezpegaldesleukin 24 µg/kg q2w First large, placebo-controlled trial to support T-reg modulation as a clinical mechanism for immunoregulation of chronic inflammatory...Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer
NEEDHAM, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced the publication of results from the Company’s randomized, double-blind, placebo-controlled, multicenter pivotal phase 3 clinical trial of aglatimagene in patients with intermediate- to high-risk localized prostate cancer,
Read more news
Top Media & Internet Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding The Lancet
Sign Up For FreeTo access detailed company insights
Founded in 1823, The Lancet is an independent, international weekly general medical journal that is committed to applying scientific knowledge to improve health and advance human progress. The company is headquartered in London, United Kingdom.... Read More
